The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.


Updates from The Motley Fool

Latest updates on Biogen from Fool.com.  The Fool has written over 500 articles on Biogen.
Is Biogen a Risky Stock?

Industry Focus' crew tries to figure out whether Biogen will reward investors in 2017.

2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...



Stock Performance

View Interactive BIIB Charts
Sponsored by

Key Data Points

Primary metrics and data points about Biogen.
Current Price: $290.65
Prev Close: $291.13
Open: $290.13
Bid: $290.03
Ask: $290.28
Day's Range: $288.55 - $291.42
52wk Range: $223.02 - $333.65
Volume: 282,178
Avg Vol 1,782,679
Market Cap: $63B
P/E (ttm): 17.20
EPS (ttm): $16.93
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Biogen.
CAPS Rating 5 out of 5
 
1002 Outperform
68 Underperform
CAPS All Stars
 
254 Outperform
12 Underperform

How do you think Biogen will perform against the market?



You pick for Biogen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Michel Vounatsos, CEO

50% Approve

Based on 5 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Biogen.

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers